Targeting Acute Myeloid Leukemia through Multi-Functional Small Molecules: Insights from Cheminformatics and Mitochondrial Modulation

MedXY Editorial Team•Sep 1, 2026•Hematology-Oncology

Novel PS127-family compounds identified via cheminformatic screening exhibit selective cytotoxicity against AML through combined induction of apoptosis, autophagy, and glutathione reductase inhibition.
These compounds provoke mitochondrial dysfunction characterized by increased reactive oxygen species (ROS), decreased oxygen consumption, and reduced ATP synthesis.
The compounds demonstrate synergistic anti-leukemic effects with standard therapeutic agents midostaurin, venetoclax, and doxorubicin, validated in both AML cell lines and patient-derived primary cells.
Cheminformatics-based function prediction successfully guided identification of structurally diverse molecules with consistent AML-targeting phenotypes, underscoring translational potential.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Novel PS127-family compounds identified via cheminformatic screening exhibit selective cytotoxicity against AML through combined induction of apoptosis, autophagy, and glutathione reductase inhibition.
These compounds provoke mitochondrial dysfunction characterized by increased reactive oxygen species (ROS), decreased oxygen consumption, and reduced ATP synthesis.
The compounds demonstrate synergistic anti-leukemic effects with standard therapeutic agents midostaurin, venetoclax, and doxorubicin, validated in both AML cell lines and patient-derived primary cells.
Cheminformatics-based function prediction successfully guided identification of structurally diverse molecules with consistent AML-targeting phenotypes, underscoring translational potential.